NGM
Income statement / Annual
Last year (2023), NGM Biopharmaceuticals, Inc.'s total revenue was $4.42 M,
a decrease of 92.02% from the previous year.
In 2023, NGM Biopharmaceuticals, Inc.'s net income was -$142.38 M.
See NGM Biopharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$4.42 M
|
$55.33 M
|
$77.88 M
|
$87.37 M
|
$103.54 M
|
$108.67 M
|
$77.14 M
|
$85.59 M
|
| Cost of Revenue |
$2.22 M |
$5.98 M |
$7.90 M |
$163.97 M |
$129.25 M |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$2.20 M |
$49.35 M |
$69.98 M |
-$76.60 M |
-$25.71 M |
$108.67 M |
$77.14 M |
$85.59 M |
| Gross Profit Ratio |
0.5 |
0.89 |
0.9 |
-0.88 |
-0.25 |
1 |
1 |
1 |
| Research and Development
Expenses |
$112.01 M
|
$181.07 M
|
$161.71 M
|
$163.97 M
|
$129.25 M
|
$95.71 M
|
$79.74 M
|
$82.11 M
|
| General & Administrative
Expenses |
$37.84 M
|
$40.52 M
|
$36.87 M
|
$27.23 M
|
$23.63 M
|
$17.27 M
|
$14.83 M
|
$11.85 M
|
| Selling & Marketing
Expenses |
-$1.11 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$36.74 M
|
$40.52 M
|
$36.87 M
|
$27.23 M
|
$23.63 M
|
$17.27 M
|
$14.83 M
|
$11.85 M
|
| Other Expenses |
-$234,000.00 |
-$132,000.00 |
-$60,000.00 |
-$593,000.00 |
-$147,000.00 |
$199,000.00 |
-$152,000.00 |
$133,000.00 |
| Operating Expenses |
$148.74 M |
$221.58 M |
$198.58 M |
$191.20 M |
$152.88 M |
$112.98 M |
$94.57 M |
$93.95 M |
| Cost And Expenses |
$150.96 M |
$221.58 M |
$198.58 M |
$191.20 M |
$152.88 M |
$112.98 M |
$94.57 M |
$93.95 M |
| Interest Income |
$9.32 M |
$3.71 M |
$420,000.00 |
$1.94 M |
$6.69 M |
$3.62 M |
$2.36 M |
$1.81 M |
| Interest Expense |
$0.00 |
$3.71 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$2.22 M
|
$4.04 M
|
$6.09 M
|
$6.56 M
|
$7.61 M
|
$7.22 M
|
$6.44 M
|
$3.53 M
|
| EBITDA |
-$144.33 M
|
-$166.25 M
|
-$120.70 M
|
-$103.83 M
|
-$49.34 M
|
$2.91 M
|
-$10.98 M
|
-$4.83 M
|
| EBITDA Ratio |
-32.68 |
-3 |
-1.55 |
-1.19 |
-0.48 |
0.03 |
-0.14 |
-0.06 |
| Operating Income Ratio
|
-33.18
|
-3
|
-1.55
|
-1.19
|
-0.48
|
-0.04
|
-0.23
|
-0.1
|
| Total Other
Income/Expenses Net |
$4.17 M
|
$3.58 M
|
$360,000.00
|
$1.35 M
|
$6.55 M
|
$3.82 M
|
$2.21 M
|
$1.94 M
|
| Income Before Tax |
-$142.38 M |
-$162.67 M |
-$120.34 M |
-$102.49 M |
-$42.80 M |
-$493,000.00 |
-$15.22 M |
-$6.42 M |
| Income Before Tax Ratio
|
-32.23
|
-2.94
|
-1.55
|
-1.17
|
-0.41
|
-0
|
-0.2
|
-0.08
|
| Income Tax Expense |
$0.00 |
-$3.58 M |
-$6.51 M |
-$8.49 M |
-$14.30 M |
$3.82 M |
-$1.06 M |
$500,000.00 |
| Net Income |
-$142.38 M |
-$159.09 M |
-$113.83 M |
-$93.99 M |
-$28.50 M |
-$493,000.00 |
-$14.16 M |
-$6.92 M |
| Net Income Ratio |
-32.23 |
-2.88 |
-1.46 |
-1.08 |
-0.28 |
-0 |
-0.18 |
-0.08 |
| EPS |
-1.73 |
-1.99 |
-1.48 |
-1.37 |
-0.57 |
-0.0076 |
-0.26 |
-0.13 |
| EPS Diluted |
-1.73 |
-1.99 |
-1.48 |
-1.37 |
-0.57 |
-0.0076 |
-0.26 |
-0.13 |
| Weighted Average Shares
Out |
$82.50 M
|
$79.95 M
|
$77.09 M
|
$68.48 M
|
$50.30 M
|
$64.99 M
|
$53.65 M
|
$53.65 M
|
| Weighted Average Shares
Out Diluted |
$82.50 M
|
$79.95 M
|
$77.09 M
|
$68.48 M
|
$50.30 M
|
$64.99 M
|
$53.65 M
|
$53.65 M
|
| Link |
|
|
|
|
|
|
|
|
